An interventional study of Prevalence (percentage) of ASD, ADHD and IDD in the studied population (homeless people sheltered in accommodation and social rehabilitation centers). in Neurodevelopmental Disorders, sponsored by Hôpital le Vinatier. Recruiting at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by Hôpital le Vinatier · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Neurodevelopmental Disorders with a site in France — 31 open to participants now, 33 under way, 5 of them phase 3. Neurodevelopmental Disorders · France.
Among the 50 studies in Neurodevelopmental Disorders with a site in France, this one is the 11th largest by planned enrollment of the 25 interventional ones that give a count, is one of 12 that started in 2026, is one of 17 with no phase, reaches primary completion later than 12 of the 32 other live ones, and was the 35th registered.
353 studies on the registry are indexed under Neurodevelopmental Disorders; 142 are open to participants now.
Browse Neurodevelopmental Disorders studies →31 of the 50 studies in Neurodevelopmental Disorders with a site in France are open now. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in France, United States, Spain
Ages up to 17
Hospices Civils de Lyon · Sites in France
Ages 5–50
Vastra Gotaland Region · Sites in France, Belgium, Denmark and 4 more countries
Ages 5–8
University Hospital, Tours · Sites in France
Ages 6–45 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 8–16
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 100 Neurodevelopmental Disorders studies recruiting now, 20 (20%) set no upper age limit and 76 (76%) stop at 75 or younger; 86 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 88 across 217 interventional studies indexed under Neurodevelopmental Disorders.
Median enrollment 132 across the 25 interventional studies, 200 across the 25 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 50 have an industry lead sponsor. The 10 most frequent:
Hôpital le Vinatier is the lead sponsor of 106 studies on the registry; 41 are open to participants now.
Hôpital le Vinatier has 1 study filed under Neurodevelopmental Disorders — fewer than ten, so there is no comparison to draw.
11 of the studies in Neurodevelopmental Disorders with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT07224581Phase 3GRIN Therapeutics, Inc.Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder | 2027-05 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
| NCT04952870University Hospital, LillePerinatal Covid-19 Infection, NO Pathway, and Minipuberty | 2026-11 |
| NCT05512637University Hospital, MontpellierScreening for Neurodevelopmental Disorders in Siblings of Children With Autism Diagnosed in Tertiary Centers | 2026-11 |
Add all 11 to your calendar (.ics) → With an account.
Among the 50 studies in Neurodevelopmental Disorders with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Introduction \& Central question: Psychiatric disorders are highly prevalent in the homeless population, however neurodevelopmental disorders are also at risk of leading to homelessness (Churchard et al., 2018; Casey et al., 2020). Research on this topic is poor in France. This research aims to study the prevalence in France of 3 neurodevelopmental disorders (NDDs) in a homeless population (Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Intellectual Developmental Disorder).
Methods / approach: A 2 phase approach will be used including a screening phase and a diagnosis phase. This research is a pilot study that will include 150 homeless people, over 2 years. The assessment involves combining the results from standardised self-report tools, direct observation and informant-report, thus guaranteeing an objective and thorough diagnosis. This approach gives a better picture of actual behaviour but also a better understanding of the person's development.
OUTCOME: This study will give insight on how to better understand the profile of the homeless population in France, and the prevalence of autism in this population. It will also bring valuable knowledge on how autism and other NDDs can impact one's path in life and lead to homelessness. The results can help develop targeted cares and measures for homeless people with NDDs.
Scientific justification : The main neurodevelopmental disorders (NDDs) are Autism Spectrum Disorder (ASD), Attention-Deficit/Hyperactivity Disorder (ADHD), Intellectual Disability (ID), Specific Learning Disorders and Neurodevelopmental Motor Disorders. This study will focus on three NDDs: ASD, ADHD and ID. Cleaton \& Kirby (2018) point out an accumulation and adversity problematic: people with NDDs would accumulate problems over time "in a cascading and cumulative manner" that would lead to adverse medical, psychological and psychosocial outcomes. Many studies have shown the poor outcomes in NDDs. People with ADHD have higher risks of imprisonment (Young \& Thome, 2011), poor educational achievement (Fleming et al., 2017), thus unemployment (Halmøy et al., 2009), leading to poor quality of life (Agarwal et al., 2012). ASD has also been linked to unemployment (Bush \& Tassé, 2017) or at least to low earnings (Roux et al., 2013), leading to lower quality of life (Ikeda et al., 2014). Unsurprisingly, ID has also been showed to lead to poorer quality of life (Simões \& Santos, 2016), because of the higher risk of risky behaviours (Fogden et al., 2016). Thus, all these reasons can lead to social isolation, difficulties in establishing independent living and vulnerability. Homelessness can arise from vulnerability, as much as it can cause it. Homelessness refers to rough sleeping (to sleep in the open air or in places not intended for human habitation, Crisis, 2017.), but also to people who sleep in adapted sleeping places but who do not have any official title to the accommodation (Fazel et al., 2014). A recent French study (Laporte et al., 2018) concluded that more than 30% of homeless people suffer from mental health disorder (13.2% would have psychosis, 12.3% severe anxiety disorder, 6.7% severe mood disorder). There is an increasing number of studies linking mental health and homelessness, however research on NDDs and homelessness is still rather poor. Two British studies have found a high prevalence of ASD among homeless adults. They explain this prevalence by the difficulty for these people to get and keep a job (Churchard et al., 2018; Kargas et al., 2019). Kargas et al., 2019 have found that 18.5% of their homeless population presented with scores superior to 7 at the AQ-10, consistent with high levels of autistic traits. A prospective study has shown that out of 135 children with ADHD, 23.9% have known homelessness at least once in their adult life (García Murillo et al., 2016). Riglin et al., (2023) explain that 20% of young socially precarious adults would suffer from ADHD. Durbin et al., (2018) claim that the prevalence of ID in a homeless population would be between 12 and 39%, this is corroborated by Brown \& McCann., (2021) who point out that 10 to 39% of homeless people would have an ID. These international studies point out the probable links between homelessness and NDDs, however this field of research is lacking in France.
Main aim of the study : to study the prevalence of the following 3 NDDs (ASD, ADHD, IDD) in a homeless population received in accommodation and social rehabilitation centres
Secondary aims :
Methodology :
This study is an observational prospective multi-centric non interventional study.
Screening :
Population studied: Homeless people sheltered in accommodation and social rehabilitation centres
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Every person who hasn't given their written .
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prevalence (percentage) of ASD, ADHD and IDD in the studied population (homeless people sheltered in accommodation and social rehabilitation centers).
Diagnostic Test: Prevalence (percentage) of ASD, ADHD and IDD in the studied population (homeless people sheltered in accommodation and social rehabilitation centers).
This study is an observational prospective multi-centric non interventional study. The focus of the study is a homeless population sheltered in accommodation and social rehabilitation centres. The prevalence of neurodevelopmental disorders in this population will be studied.
Prevalence (percentage) of ASD, ADHD and IDD in the studied population (homeless people sheltered in accommodation and social rehabilitation centers).
For each NDD here are the scores and tools used : ASD : * AQ-10 cut-off score * CAT-Q cut-off score(Camouflage of Autistic Traits Questionnaire) * Glasgow questionnaire : standard score deviations * DATHi (DSM-5 Autistic Traits in the Homeless Interview) : cut-off score ADHD: * ADHD Self-report (ASRS) : cut-off score * Diagnostic Interview for Adult ADHD (DUVA-5): cut-off score * ASRS - Observer : cut-off score IDD: * Raven matrices: score * Vineland Adaptive Behaviour Scale (2nd edition): cut-off score
Time frame: 4 months
Demographic information
Age, education, professional career, time without a home and duration of homelessness The measures will be in number of weeks, months or years
Time frame: 4 months
Judicial information
Record of conviction, sentences and imprisonment
Time frame: 4 months
Medical Record
Medical treatments, care, mental health issues
Time frame: 4 months
Drug abuse
History of drug abuse, which drugs, quantities
Time frame: 4 months
History of traumatic brain injury, epilepsy and coma
History of traumatic brain injury (yes / no); coma (yes /no); epilepsy (yes / no)
Time frame: 4 months
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.
Of 142 non-industry interventional studies with no phase under Neurodevelopmental Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 12 months is below that.
Counting every sponsor, half of 148 studies reached it within 30 months; a quarter within 15 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neurodevelopmental Disorders →